TY - JOUR
T1 - High-precision multiclass cell classification by supervised machine learning on lectin microarray data
AU - Shibata, Mayu
AU - Okamura, Kohji
AU - Yura, Kei
AU - Umezawa, Akihiro
N1 - Funding Information:
This research was supported by grants from the Ministry of Education, Culture, Sports, Science, and Technology ( MEXT ) of Japan; by Ministry of Health, Labor and Welfare ( MHLW ) Sciences research grants. KY was supported by Platform Project for Supporting Drug Discovery and Life Science Research (Basis for Supporting Innovative Drug Discovery and Life Science Research (BINDS)) from AMED under Grant Number JP20am0101065 .
Funding Information:
We express our sincere appreciation to Catherine Ketcham for reviewing the manuscript, Masao Yamada and Koichiro Nishino for fruitful discussion, Yoshihiro Nishijima, Masashi Toyoda and Mayu Yamazaki-Inoue for providing the lectin microarray data. Computational time was provided by the HA8000/RS210 cluster and cluster of HPE ProLiant DL360 Gen 10 at the Center for Regenerative Medicine, National Research Institute for Child Health and Development. This work was supported by National Institute for Child Health and Development Research Institute, Japan.
Publisher Copyright:
© 2020 The Japanese Society for Regenerative Medicine
PY - 2020/12
Y1 - 2020/12
N2 - Introduction: Establishment of a cell classification platform for evaluation and selection of human pluripotent stem cells (hPSCs) is of great importance to assure the efficacy and safety of cell-based therapy. In our previous work, we introduced a discriminant function that evaluates pluripotency from the cells’ glycome. However, it is not yet suitable for general use. Methods: The current study aims to establish a high-precision cell classification platform introducing supervised machine learning and test the platform on glycome analysis as a proof-of-concept study. We employed linear classification and neural network to the lectin microarray data from 1577 human cells and categorized them into five classes including hPSCs. Results: The linear-classification-based model and the neural-network-based model successfully predicted the sample type with accuracies of 89% and 97%, respectively. Conclusions: Because of the high recognition accuracies and the small amount of computing resources required for these analyses, our platform can be a high precision conventional cell classification system for hPSCs.
AB - Introduction: Establishment of a cell classification platform for evaluation and selection of human pluripotent stem cells (hPSCs) is of great importance to assure the efficacy and safety of cell-based therapy. In our previous work, we introduced a discriminant function that evaluates pluripotency from the cells’ glycome. However, it is not yet suitable for general use. Methods: The current study aims to establish a high-precision cell classification platform introducing supervised machine learning and test the platform on glycome analysis as a proof-of-concept study. We employed linear classification and neural network to the lectin microarray data from 1577 human cells and categorized them into five classes including hPSCs. Results: The linear-classification-based model and the neural-network-based model successfully predicted the sample type with accuracies of 89% and 97%, respectively. Conclusions: Because of the high recognition accuracies and the small amount of computing resources required for these analyses, our platform can be a high precision conventional cell classification system for hPSCs.
KW - Artificial intelligence
KW - Lectin microarray
KW - Linear classification
KW - Neural network
KW - Pluripotent stem cells
UR - http://www.scopus.com/inward/record.url?scp=85092744936&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85092744936&partnerID=8YFLogxK
U2 - 10.1016/j.reth.2020.09.005
DO - 10.1016/j.reth.2020.09.005
M3 - Article
AN - SCOPUS:85092744936
SN - 2352-3204
VL - 15
SP - 195
EP - 201
JO - Regenerative Therapy
JF - Regenerative Therapy
ER -